Seer rejects acquisition proposals, cites undervaluation

Seer Inc. (SEER) rejected two acquisition proposals, citing undervaluation. The offers were $2.55 and $2.45 per share, plus contingent value rights. The Special Committee, after a three-month review, concluded a sale would undervalue the company. Seer develops proteomics products for research use.

Original reporting
Published Oct 29, 2026, 8:40 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 29, 2026, 8:51 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefMergers & acquisitions
Primary signal
$SEER
Neutral
medium confidence
Mentioned
$SEER
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$SEERNeutralMed
01

Why it matters

The board’s unanimous rejection sets a valuation benchmark and can change near-term expectations for deal probability, timing, and potential bid escalation.

02

Market read

Traders may reprice Seer’s deal optionality after the rejection and watch for any revised bids or process updates.

03

What to watch

The article does not disclose Seer’s standalone valuation, financing constraints, or whether alternative counterparties showed meaningful interest, which are key drivers of whether bids reappear.

Relevance 7/10Novelty 6/10Timing: today’s M&A process update, after-hours or premarket depending on dissemination

Background

Seer announced that its independent special committee completed a three-month review of two unsolicited acquisition proposals and other strategic alternatives.

Company-level read

Ticker impact

$SEERNeutralMedium confidence
Context

Seer’s special committee rejected two unsolicited buyout proposals, saying both fail to reflect intrinsic value and would undervalue the company.

Expected impact

Likely choppy trading as deal-spread expectations reset after the rejection, with upside limited until a higher bid or new process update emerges.

Evidence & confidence

The article is a direct M&A process update for Seer, but it does not state a new bid, timing, or definitive next steps beyond rejection and valuation rationale.

Market effects

Could modestly affect sentiment for proteomics/research-instruments peers by highlighting valuation sensitivity in the segment’s M&A appetite.

Limited, as this is a single-company corporate action with no stated broader market linkage.

Low, no cross-border transaction or macro linkage is described.

Counterpoint

Rejection may be a negotiating tactic; the board’s “intrinsic value” language can precede a higher revised offer rather than ending the process.

Key entities

  • Seer, Inc.

    NASDAQ-listed proteomics products company whose special committee rejected two unsolicited acquisition proposals.

  • Bradley L. Radoff and Michael Torok (and affiliates)

    Submitted a proposal to acquire all outstanding shares for $2.55 per share in cash plus a contingent value right.

  • Omid Farokhzad, M.D.

    Submitted a separate proposal to acquire all outstanding shares for $2.45 per share in cash plus two contingent value rights.

  • Meeta Gulyani and Nicolas Roelofs, Ph.D.

    Independent directors on Seer’s special committee that rejected both proposals.

Related articles

$SEERMed

Seer Reports Third Quarter 2026 Financial Results and Updates Full Year 2026 Revenue Guidance

Seer, Inc. (SEER) filed an SEC Form 8-K — Results of Operations and Financial Condition. Seer Reports Third Quarter 2026 Financial Results and Updates Full Year 2026 Revenue Guidance REDWOOD CITY, Calif. – November 10, 2026 – Seer, Inc. (Nasdaq: SEER) (“Seer” or the “Company”), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced fin

$SEERMed

Seer wins ITC staff backing for import ban on Nanomics products

Seer, Inc. (SEER) announced that the U.S. International Trade Commission's staff recommended an import ban on Nanomics' products, alleging patent infringement. The ITC is expected to make a final decision by year-end. Seer also reported recent patent victories in the U.S. and Europe. The company develops proteomics technology and is involved in a related lawsuit against Nanomics.

$SEERMedAI 8/10

Seer Inc. Q2 2026 Earnings: Revenue Misses $3.1 Million

Seer Inc. (Nasdaq: SEER) reported Q2 2026 revenue of $3.1 million, below consensus of $4.0 million, and a net loss of $0.31 per share versus a $0.22 loss expected. The company reaffirmed full-year 2026 revenue guidance of $16 million to $18 million. Shares fell about 2.78% after hours to $2.10.